Director/PDMR Shareholding
Updated : 17:48
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Ms E Walmsley | ||||||||||||
b) | Position/status | Chief Executive Officer | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
1511 £15.766
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr R G Connor | ||||||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information Aggregated volume Price |
494 £15.766
| ||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr L Debruyne | ||||||||
b) | Position/status | President, Global Vaccines | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information Aggregated volume Price |
588 £15.766
| ||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Mr S Dingemans | ||||||||||||
b) | Position/status | Chief Financial Officer | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
1382 £15.766
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Mr N Hirons | ||||||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
398 £15.766
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr B McNamara | ||||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information Aggregated volume Price |
154 $41.75
| ||||||
e) | Date of the transaction | 2018-07-12 | ||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr L Miels | ||||
b) | Position/status | President, Global Pharmaceuticals | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2018-07-12 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Mr D S Redfern | ||||||||||||
b) | Position/status | Chief Strategy Officer | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
552 £15.766
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms K Terrell | ||||
b) | Position/status | Chief Digital & Technology Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | n/a (single transaction) | ||||
e) | Date of the transaction | 2018-07-12 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Ms C Thomas | ||||||||||||
b) | Position/status | SVP, Human Resources | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
761 £15.766
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr P C Thomson | ||||||||
b) | Position/status | President, Global Affairs | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information Aggregated volume Price |
285 £15.766
| ||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||
a) | Name | Mr D E Troy | ||||||||||||
b) | Position/status | SVP & General Counsel | ||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 July 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. | ||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||
d) | Aggregated information Aggregated volume Price |
453 $41.75
| ||||||||||||
e) | Date of the transaction | 2018-07-12 | ||||||||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.